menu
    • menu

    Company profile for ContraVir

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ContraVir is developing a portfolio of novel compounds against hepatitis B, including TXL™, a highly potent prodrug of the antiviral tenofovir (active component of both Vemlidy® and Viread®), now in Phase 2 trials, and CRV431, a next generation cyclophilin inhibitor advancing into clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ContraVirUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    399 Thornall Street, 1st Floor Edison, NJ 08837
    Telephone
    Telephone
    +732-902-4000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://contravir.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/contravir-pharmaceuticals-inc-/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ContraVirPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Stock Under Active Eyes: ContraVir Pharmaceuticals, Inc. (CTRV)
    Stock Under Active Eyes: ContraVir Pharmaceuticals, Inc. (CTRV)

    25 Jul 2018

    // BITCOINPRICE

    https://www.bitcoinpriceupdate.review/2018/07/25/stock-under-active-eyes-contravir-pharmaceuticals-inc-ctrv-2/

    BITCOINPRICE
    25 Jul 2018
    Share Share
    ContraVir Pharmaceuticals Reports Progress in Phase 1/2A Trial of CRV431
    ContraVir Pharmaceuticals Reports Progress in Phase 1/2A Trial of CRV431

    23 Jul 2018

    // PRESS RELEASE

    http://ir.contravir.com/news-releases/news-release-details/contravir-pharmaceuticals-reports-progress-phase-12a-trial

    PRESS RELEASE
    23 Jul 2018
    Share Share
    ContraVir has ‘near-term catalysts’ that should drive ‘higher valuation,’
    ContraVir has ‘near-term catalysts’ that should drive ‘higher valuation,’

    23 Jul 2018

    // PROACTIVEINVESTORS

    http://www.proactiveinvestors.com/companies/news/201374/contravir-has-near-term-catalysts-that-should-drive-higher-valuation-say-maxim-analysts-201374.html

    PROACTIVEINVESTORS
    23 Jul 2018
    Share Share
    ContraVir CEO excited to get hepatitis B drug to patients in new study
    ContraVir CEO excited to get hepatitis B drug to patients in new study

    09 Jul 2018

    // PROACTIVEINVESTORS

    http://www.proactiveinvestors.com/companies/stocktube/9802/contravir-pharmaceuticals-ceo-excited-to-get-hepatitis-b-drug-to-patients-in-new-study-9802.html

    PROACTIVEINVESTORS
    09 Jul 2018
    Share Share
    ContraVir Pharmaceuticals to Present at Virtual Investor Conference
    ContraVir Pharmaceuticals to Present at Virtual Investor Conference

    05 Jul 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/contravir-pharmaceuticals-to-present-at-virtual-investor-conference-300676434.html

    PR NEWSWIRE
    05 Jul 2018
    Share Share
    ContraVir Announces $10.8 M in Expected Gross Proceeds from Recently Expired
    ContraVir Announces $10.8 M in Expected Gross Proceeds from Recently Expired

    29 Jun 2018

    // PRESS RELEASE

    http://ir.contravir.com/news-releases/news-release-details/contravir-pharmaceuticals-announces-108-million-expected-gross

    PRESS RELEASE
    29 Jun 2018
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search